Market Overview

Allergan Reports Filing of Answer in Federal Court Related to Valeant, Pershing Square's Counterclaims

Related AGN
Ackman: Allergan Is A Good Merger Arbitrage Play, Potential 28% Upside
Benzinga's Top Downgrades
Deal Frenzy: 2014 Sees Record M&A Volume (Fox Business)
Related VRX
Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO
Where Could ValueAct Capital's New $1.5 Billion Go?
Deal Frenzy: 2014 Sees Record M&A Volume (Fox Business)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today filed an answer
in the United States District Court for the Central District of California
responding to Valeant Pharmaceuticals International, Inc. (“Valeant”) and
Pershing Square Capital Management, L.P.'s (“Pershing Square”) counterclaims
regarding Allergan's statements on the unsustainability of Valeant's
underlying business model.

The federal court case is Allergan, Inc. v. Valeant Pharmaceuticals
International, Inc., No. 14-CV-1214-DOC (ANx) (C.D. Cal.).

Posted-In: News Hedge Funds Legal Press Releases General

 

Related Articles (AGN + VRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters